Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:LGND NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.57-0.3%$9.15$6.00▼$11.31$2.44B0.574.68 million shs5.33 million shsCLDXCelldex Therapeutics$32.45-0.2%$31.94$18.55▼$35.79$2.55B0.98789,344 shs576,700 shsLGNDLigand Pharmaceuticals$218.98-1.0%$214.39$98.89▼$247.38$4.43B1.2212,691 shs151,157 shsZBIOZenas BioPharma$18.90-5.2%$21.36$8.86▼$44.60$1.14B-0.61471,559 shs510,726 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-0.31%+7.53%-1.03%+41.57%-2.84%CLDXCelldex Therapeutics-0.18%-2.61%-2.64%+41.09%+71.33%LGNDLigand Pharmaceuticals-1.01%+4.11%-5.75%+19.12%+108.37%ZBIOZenas BioPharma-5.17%-1.92%-11.43%-28.41%+117.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.57-0.3%$9.15$6.00▼$11.31$2.44B0.574.68 million shs5.33 million shsCLDXCelldex Therapeutics$32.45-0.2%$31.94$18.55▼$35.79$2.55B0.98789,344 shs576,700 shsLGNDLigand Pharmaceuticals$218.98-1.0%$214.39$98.89▼$247.38$4.43B1.2212,691 shs151,157 shsZBIOZenas BioPharma$18.90-5.2%$21.36$8.86▼$44.60$1.14B-0.61471,559 shs510,726 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-0.31%+7.53%-1.03%+41.57%-2.84%CLDXCelldex Therapeutics-0.18%-2.61%-2.64%+41.09%+71.33%LGNDLigand Pharmaceuticals-1.01%+4.11%-5.75%+19.12%+108.37%ZBIOZenas BioPharma-5.17%-1.92%-11.43%-28.41%+117.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70116.30% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7853.40% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.7117.69% UpsideZBIOZenas BioPharma 2.44Hold$44.29134.32% UpsideCurrent Analyst Ratings BreakdownLatest ZBIO, LGND, CLDX, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/14/2026ZBIOZenas BioPharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$21.00 ➝ $22.005/14/2026ZBIOZenas BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/6/2026BCRXBioCryst Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.005/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.78$1.23 per share7.75($2.18) per share-4.39CLDXCelldex Therapeutics$1.54M1,653.90N/AN/A$5.81 per share5.59LGNDLigand Pharmaceuticals$268.09M16.37$7.77 per share28.17$49.76 per share4.40ZBIOZenas BioPharma$10M108.43N/AN/A$4.51 per share4.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A16.50N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%N/ALGNDLigand Pharmaceuticals$124.45M$7.3729.7129.241.7955.95%16.19%11.13%N/AZBIOZenas BioPharma-$377.74M-$7.81N/AN/AN/AN/A-112.13%-76.14%N/ALatest ZBIO, LGND, CLDX, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/A3/16/2026Q4 2025ZBIOZenas BioPharma-$1.22-$4.54-$3.32-$4.54$28.75 millionN/A2/26/2026Q4 2025BCRXBioCryst Pharmaceuticals$0.07$1.12+$1.05$1.12$151.32 million$163.28 million2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 million2/25/2026Q4 2025CLDXCelldex Therapeutics-$1.00-$1.22-$0.22-$1.22$1.53 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92LGNDLigand Pharmaceuticals0.4521.2820.95ZBIOZenas BioPharma0.325.615.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics5.20%LGNDLigand Pharmaceuticals7.00%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million241.20 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableZBIOZenas BioPharmaN/A57.37 million44.75 millionN/AZBIO, LGND, CLDX, and BCRX HeadlinesRecent News About These CompaniesZenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Hold" from Analysts3 hours ago | americanbankingnews.comWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossMay 14 at 6:16 PM | uk.finance.yahoo.comZenas BioPharma Stock Short Interest Report | NASDAQ:ZBIO | BenzingaMay 13 at 9:36 AM | benzinga.comZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13 at 7:01 AM | globenewswire.comZenas BioPharma Highlights Strong Q1 Progress and FinancingMay 13 at 6:51 AM | tipranks.comZenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory SubmissionsMay 13 at 6:30 AM | quiverquant.comQZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13 at 6:00 AM | globenewswire.comZenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on ThursdayMay 7, 2026 | americanbankingnews.comZenas BioPharma (ZBIO) to Release Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?May 4, 2026 | marketbeat.comZenas BioPharma rises as CEO continues insider purchasesApril 30, 2026 | msn.comZenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026April 30, 2026 | seekingalpha.comZenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying ActivityApril 30, 2026 | marketbeat.comLeon Moulder, Jr. Buys 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockApril 30, 2026 | insidertrades.comLeon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockApril 29, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) CEO Acquires $616,700.00 in StockApril 29, 2026 | marketbeat.comHere’s Why Zenas BioPharma (ZBIO) Traded Lower in Q1April 21, 2026 | insidermonkey.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by AnalystsApril 20, 2026 | marketbeat.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2026 | markets.businessinsider.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2026 | globenewswire.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 21.4% in MarchApril 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZBIO, LGND, CLDX, and BCRX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.57 -0.03 (-0.31%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$9.52 -0.05 (-0.53%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$32.45 -0.06 (-0.18%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$32.24 -0.21 (-0.65%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$218.98 -2.23 (-1.01%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$218.10 -0.88 (-0.40%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Zenas BioPharma NASDAQ:ZBIO$18.90 -1.03 (-5.17%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$19.26 +0.36 (+1.91%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
